Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
What's New in the Guidelines
Last Updated: December 12, 2019; Last Reviewed: December 12, 2019
Use of Dolutegravir in Pregnant Women and Women Who Are Trying to Conceive
The Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission (the Panel) has updated recommendations regarding the use of dolutegravir (DTG) in pregnant women and women who are trying to conceive based on data available as of August 2019.
Restrictions on use of DTG during the first trimester and in women who are trying to conceive have been removed. DTG is now a Preferred antiretroviral (ARV) drug throughout pregnancy and an Alternative ARV drug for women who are trying to conceive. Panel members weighed not only the updated data about DTG-associated risk of infant neural tube defects (NTDs) in Botswana, but also the important lack of comparable data about the risk of NTDs when using DTG in other settings, and what is known about the risk of NTDs and other adverse pregnancy outcomes, such as preterm birth, when using other Preferred and Alternative ARV drugs and drug combinations. The Panel has emphasized the importance of counseling and informed decision-making regarding all ARV regimens for people with HIV, and has added a guide to assist health care providers in counseling patients about the use of DTG.
The sections listed below were revised to include updated data, recommendations, and guidance about the use of DTG in pregnant women and in women who are trying to conceive:
- Teratogenicity
- Recommendations for Use of Antiretroviral Drugs During Pregnancy
- Pregnant Women Living with HIV Who Have Never Received Antiretroviral Drugs
- Pregnant Women Living with HIV Who are Currently Receiving Antiretroviral Therapy
- HIV-2 Infection and Pregnancy
- Acute HIV Infection
- Dolutegravir
- Appendix D. Dolutegravir Counseling Guide for Health Care Providers
Download Guidelines
- Section Only PDF (245 KB)
- Full Guideline PDF (3 MB)
- Recommendations Only PDF (211 KB)
- Tables Only PDF (388 KB)
Related Content
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive